Pyxis Oncology Inc PYXS
News
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
